Residual effect of Covid-19
Conditions
Interventions
This is a controlled, randomized, parallel, 1:1 scale clinical trial. Symptomatic patients will be randomly allocated, by drawing lots, into two groups, namely: Group 0 (control): patients who will re
Sponsors
Faculdade de Medicina - Universidade do Estado de São Paulo (Unesp) - Campus Botucatu
Faculdade de Medicina - Universidade do Estado de São Paulo (Unesp) - Campus Botucatu
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients of both sexes; Present respiratory disease, with at least 3 (three) of the following symptoms: fever, chills, fatigue, myalgia, anorexia, sore throat, cough, expectoration, dyspnea, chest pain, headache, nasal congestion, conjunctival congestion, coryza , anosmia or hyposmia, dysgeusia, abdominal pain, diarrhea, rash; Present physical symptoms related to Covid-19 infection at the time of the first homeopathic consultation (symptomatic patients); Present a positive laboratory test (RT-PCR or serological) confirmed for COVID-19; Be = 18 years of age; Not having the following comorbidities: severe heart disease (chronic or congenital), poorly controlled heart failure, poorly controlled COPD and asthma, cystic fibrosis with recurrent infections, chronic kidney disease at an advanced stage or undergoing dialysis, immunosuppressed, solid organ and bone marrow transplants; Sign the Free and Informed Consent Term (ICF) authorizing your participation in the research
Exclusion criteria
Exclusion criteria: Individuals who no longer wish to participate in the clinical follow-up performed by the physician; Patients who fail to follow the therapeutic guidelines for the use of homeopathic medication as recommended (misuse, discontinuation of use); Asymptomatic patients for Covid-19, even with positive serological test or RT-PCR.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| As a primary outcome, it is expected to observe a change in the individualized global score of COVID-19 and treatment time, through questionnaires (clinical sheets) developed for this research, containing the peculiar symptoms of Covid-19, listed by the Ministry of Health, and intensity score for each of them, being 0 (no symptoms), 1 (mild symptom), 2 (moderate symptom) and 3 (severe symptom). The sum of all points of all symptoms will be graded from 1 to 72 points, depending on the intensity of symptoms and overall sum assigned at each visit. It is expected to observe a reduction in the general score in the 72-hour and 120-hour consultations, as well as at the time of medical discharge. The total score score at the various time points will then be compared between the intervention and control groups. It is intended to observe whether there is a difference in the score at each moment and between the groups. The questionnaires also allow observing the average time of improvement of the clinical condition, from the first consultation questionnaire, follow-up consultations, until the medical discharge consultation. | — |
Secondary
| Measure | Time frame |
|---|---|
| As secondary outcomes, we intend to verify the change in the assessment of the mental health status of patients in follow-up, through mental scale assessment (HADS), realizing possible reductions in the impacts of mental suffering reported during the pandemic, as well as evaluating the event of residual symptoms. persistent through the score obtained in the interviews following the clinical form developed for this purpose, and the application of the mental suffering scale (HADS). | — |
Countries
Brazil
Contacts
Public ContactRenata Lemonica
Faculdade de Medicina - Universidade do Estado de São Paulo (Unesp) - Campus Botucatu
Outcome results
None listed